BridgeBio Oncology Therapeutics, Inc. Cash and Restricted Cash
BridgeBio Oncology Therapeutics, Inc. (BBOT) had Cash and Restricted Cash of $54.20 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $54.20M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $52.79M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $373.82M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $408.87M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $54.20M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $52.79M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $373.82M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $408.87M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $31.65M 10-Q · filed 2026-08-11 | $664.23K 10-Q · filed 2025-08-01 |
| 2025-03-31 | $26.35M 10-Q · filed 2026-05-12 | $963.13K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $30.98M 10-Q · filed 2026-08-11 | $1.70M 10-K · filed 2025-03-11 |
| 2024-09-30 | $20.41M 10-Q · filed 2025-11-12 | $1.79M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.81M 10-Q · filed 2025-08-01 | |
| 2024-03-31 | $1.84M 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $250.00K POS AM · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |